Personalized mRNA melanoma vaccine trims five-year recurrence risk by almost 50%, Moderna and Merck report
TL;DR Summary
In a Phase 2 trial of 157 high‑risk stage 3/4 melanoma patients, Moderna and Merck’s personalized mRNA vaccine (mRNA-4157) plus Keytruda reduced recurrence or death at five years by about 49% versus Keytruda alone. Earlier two- and three-year data showed similar risk reductions (44% and 49%). Safety was similar between groups, with fatigue, injection-site pain, and chills most common. Full data aren’t yet published; a Phase 3 trial is underway and more data from this program are expected.
- mRNA cancer vaccine shows protection at 5-year follow-up, Moderna and Merck say Ars Technica
- Moderna, Merck Report Positive Results From Cancer-Vaccine Study The Wall Street Journal
- This innovation saved lives in the pandemic. Now it’s showing strength against cancer. The Washington Post
- Moderna, Merck & Co. cancer vaccine combo holds edge over Keytruda at five-year mark FirstWord Pharma
- Vaccine for aggressive skin cancer shows promising results in trials Euronews.com
Reading Insights
Total Reads
0
Unique Readers
12
Time Saved
4 min
vs 5 min read
Condensed
92%
971 → 78 words
Want the full story? Read the original article
Read on Ars Technica